Preclinical relaxin therapy to reverse cardiac fibrosis and gain functional benefits

心脏纤维化是促进心脏病和并发症（包括心律失常和心力衰竭）发生的关键因素。对可以逆转纤维化的药物存在迫切且未满足的需求。通过记录肽激素松弛素的抗纤维化作用，CIA和他的团队将测试松弛素在心脏病模型中的治疗效果，重点是纤维化逆转和功能获得，特别是心律失常。这一工作将促进松弛素作为一种新型心血管药物的开发。

Cardiac fibrosis is a key factor promoting heart disease and onset of complications including arrhythmias and heart failure. There is urgent and unmet need of drugs that can reverse fibrosis. By documenting anti-fibrotic action of a peptide hormone relaxin, CIA and his team will test therapeutic effect of relaxin in heart disease models focusing on fibrosis-reversal and functional gain, particularly arrhythmias. This work would promote development of relaxin as a new cardiovascular drug.